Pressure-inactivated yellow fever 17DD virus:: Implications for vaccine development

被引:43
|
作者
Gaspar, Luciane P. [1 ]
Mendes, Ygara S. [2 ,3 ]
Yamamura, Anna M. Y. [1 ]
Almeida, Luiz F. C. [1 ]
Caride, Elena [1 ]
Goncalves, Rafael B. [2 ,3 ]
Silva, Jerson L. [2 ,3 ]
Oliveira, Andrea C. [2 ,3 ]
Galler, Ricardo [1 ]
Freire, Marcos S. [1 ]
机构
[1] Fundacao Oswaldo Cruz, Inst Tecnol Imunobiol, Programa Vacinas Virais, BR-21045900 Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Biol Estrutural, BR-21941590 Rio De Janeiro, Brazil
[3] Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Macromol Jiri Jo, Programa Biol Estrutural, BR-21941590 Rio De Janeiro, Brazil
关键词
Yellow Fever 17DD virus; high pressure; virus inactivation;
D O I
10.1016/j.jviromet.2008.03.002
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The successful Yellow Fever (YF) vaccine consists of the live attenuated 17D-204 or 17DD Viruses. Despite its excellent record of efficacy and safety, serious adverse events have been recorded and influenced extensive vaccination in endemic areas. Therefore, alternative strategies should be considered, which may include inactivated whole virus. High hydrostatic pressure has been described as a method for viral inactivation and vaccine development. The present study evaluated whether high hydrostatic pressure would inactivate the YF 17DD virus. YF 17DD virus was grown in Vero cells in roller bottle cultures and subjected to 310 MPa for 3 h at 4 degrees C. This treatment abolished YF infectivity and eliminated the ability of the virus to cause disease in mice. Pressure-inactivated virus elicited low level of neutralizing antibody titers although exhibited complete protection against an otherwise lethal challenge with 17DD virus in the murine model. The data warrant further development of pressure-inactivated vaccine against YF. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 50 条
  • [41] Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases (vol 358, pg 91, 2001)
    Vasconcelos, P
    LANCET, 2001, 358 (9278): : 336 - 336
  • [42] 17D Yellow Fever Virus Vaccine
    Monath, Thomas P.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2013, 89 (06): : 1225 - 1225
  • [43] Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity
    Monath, Thomas P.
    Lee, Cynthia K.
    Julander, Justin G.
    Brown, Alicja
    Beasley, David W.
    Watts, Douglas M.
    Hayman, Edward
    Guertin, Patrick
    Makowiecki, Joseph
    Crowell, Joseph
    Levesque, Philip
    Bowick, Gavin C.
    Morin, Merribeth
    Fowler, Elizabeth
    Trent, Dennis W.
    VACCINE, 2010, 28 (22) : 3827 - 3840
  • [44] The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil
    Suzano, CES
    Amaral, E
    Sato, HK
    Papaiordanou, PM
    VACCINE, 2006, 24 (09) : 1421 - 1426
  • [45] 17DD and 17D-213/77 Yellow Fever Substrains Trigger a Balanced Cytokine Profile in Primary Vaccinated Children
    Campi-Azevedo, Ana Carolina
    de Araujo-Porto, Luiza Pacheco
    Luiza-Silva, Maria
    Batista, Mauricio Azevedo
    Martins, Marina Angela
    Sathler-Avelar, Renato
    da Silveira-Lemos, Denise
    Bastos Camacho, Luiz Antonio
    Martins, Reinaldo de Menezes
    de Sousa Maia, Maria de Lourdes
    Guedes Farias, Roberto Henrique
    Freire, Marcos da Silva
    Galler, Ricardo
    Homma, Akira
    Leite Ribeiro, Jose Geraldo
    Campos Lemos, Jandira Aparecida
    Auxiliadora-Martins, Maria
    Caldas, Iramaya Rodrigues
    Eloi-Santos, Silvana Maria
    Teixeira-Carvalho, Andrea
    Martins-Filho, Olindo Assis
    PLOS ONE, 2012, 7 (12):
  • [46] 17D Yellow Fever Virus Vaccine Response
    Edupuganti, Srilatha
    Mulligan, Mark J.
    Eidex, Rachel B.
    Cetron, Martin
    Marfin, Anthony A.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2013, 89 (06): : 1226 - 1227
  • [47] Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture
    Pato, Tania P.
    Souza, Marta C. O.
    Mattos, Diogo A.
    Caride, Elena
    Ferreira, Davis F.
    Gaspar, Luciane P.
    Freire, Marcos S.
    Castilho, Leda R.
    VACCINE, 2019, 37 (24) : 3214 - 3220
  • [48] C-leptin type receptor 5 and IFN-gamma gene expression and polymorphisms as markers for 17DD Yellow Fever vaccine immune response
    Azamor, T.
    Silva, A. M. V.
    Carvalho, C. X.
    Alvarado-Arnez, L.
    Melgaco, J. G.
    Bayma, C.
    Ano Bom, A. D.
    Moraes, M. O.
    Neves, P. C. C.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 987 - 988
  • [49] Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo
    Nzolo, Didier
    Biongo, Aline Engo
    Kuemmerle, Andrea
    Lusakibanza, Mariano
    Lula, Yves
    Nsengi, Ntamabyaliro
    Ndosimao, Celestin Nsibu
    Lutete, Gaston Tona
    Van Geertruyden, Jean-Pierre
    VACCINE, 2018, 36 (41) : 6170 - 6182
  • [50] Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos
    Marchevsky, Renato S.
    da Luz Leal, Maria
    Homma, Akira
    Coutinho, Evandro S. F.
    Camacho, Luis A. B.
    Jabor, Alfredo V.
    Galler, Ricardo
    Freire, Marcos S.
    BIOLOGICALS, 2006, 34 (03) : 191 - 197